BR112014019611A2 - agentes de ligação mica - Google Patents

agentes de ligação mica

Info

Publication number
BR112014019611A2
BR112014019611A2 BR112014019611A BR112014019611A BR112014019611A2 BR 112014019611 A2 BR112014019611 A2 BR 112014019611A2 BR 112014019611 A BR112014019611 A BR 112014019611A BR 112014019611 A BR112014019611 A BR 112014019611A BR 112014019611 A2 BR112014019611 A2 BR 112014019611A2
Authority
BR
Brazil
Prior art keywords
antibodies
mica
binding agents
mica binding
derivatives
Prior art date
Application number
BR112014019611A
Other languages
English (en)
Portuguese (pt)
Inventor
Bonnafous Cecile
Perrot Ivan
Gauthier Laurent
Blery Mathieu
Original Assignee
Innate Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Pharma filed Critical Innate Pharma
Publication of BR112014019611A2 publication Critical patent/BR112014019611A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BR112014019611A 2012-02-07 2013-02-07 agentes de ligação mica BR112014019611A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261595902P 2012-02-07 2012-02-07
US201261625841P 2012-04-18 2012-04-18
PCT/EP2013/052439 WO2013117647A1 (en) 2012-02-07 2013-02-07 Mica binding agents

Publications (1)

Publication Number Publication Date
BR112014019611A2 true BR112014019611A2 (pt) 2017-06-27

Family

ID=47714068

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014019611A BR112014019611A2 (pt) 2012-02-07 2013-02-07 agentes de ligação mica

Country Status (11)

Country Link
US (2) US10577416B2 (enExample)
EP (1) EP2812027A1 (enExample)
JP (1) JP6405242B2 (enExample)
CN (1) CN104244977A (enExample)
AU (1) AU2013218017B2 (enExample)
BR (1) BR112014019611A2 (enExample)
CA (1) CA2862101A1 (enExample)
IL (1) IL233793B (enExample)
RU (1) RU2656183C2 (enExample)
SG (1) SG11201404177PA (enExample)
WO (1) WO2013117647A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX355877B (es) * 2011-09-30 2018-05-03 Dana Farber Cancer Inst Inc Peptidos terapeuticos.
CN104244977A (zh) 2012-02-07 2014-12-24 先天制药公司 Mica结合剂
US10745483B2 (en) 2013-03-15 2020-08-18 Dana-Farber Cancer Institute, Inc. Therapeutic peptides
AU2014229476B2 (en) 2013-03-15 2019-07-11 Novelogics Biotechnology, Inc. Antibodies to MICA and MICB proteins
US10106611B2 (en) * 2013-12-06 2018-10-23 Dana-Farber Cancer Institute, Inc. Antibodies that bind to MHC class I polypeptide-related sequence A
JP2017510631A (ja) 2014-03-14 2017-04-13 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 癌に対しｎｋｇ２ｄ経路機能を回復させるためのワクチン組成物および方法
DK3227311T3 (da) * 2014-12-05 2022-03-07 Xyphos Biosciences Inc Indsættelige, variable fragmenter af antistoffer og modificerede A1- A2-domæner af NKG2D-ligander
EP3270937A4 (en) * 2015-03-26 2018-09-12 The Trustees Of Dartmouth College Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using
AU2016299166B2 (en) 2015-07-24 2022-03-31 Innate Pharma Methods for detecting tissue infiltrating NK cells
CR20180350A (es) * 2015-12-04 2018-10-02 Dana Farber Cancer Inst Inc Vacunación con el dominio alfa 3 de mica/b para el tratamiento del cáncer
WO2017147247A1 (en) * 2016-02-23 2017-08-31 Pires Eusebio S Anti-sas1b antibodies and methods of use
KR20180118673A (ko) * 2016-03-15 2018-10-31 이나뜨 파르마 항-mica 항체
CN107779433A (zh) * 2016-08-30 2018-03-09 天津市康婷生物工程有限公司 便捷的刺激nk细胞增殖和分化的饲养层制备方法
AU2017344411A1 (en) * 2016-10-19 2019-05-09 Novelogics Biotechnology, Inc. Antibodies to MICA and MICB proteins
CN107964041B (zh) * 2016-10-20 2023-08-01 中国科学院广州生物医药与健康研究院 高稳定性和高亲和力的dmic及其制法
JP2019535250A (ja) * 2016-10-29 2019-12-12 ジェネンテック， インコーポレイテッド 抗ｍｉｃ抗体及び使用方法
CA3047833A1 (en) 2016-12-22 2018-06-28 Icahn School Of Medicine At Mount Sinai Anti-lilrb3 antibodies and methods of use thereof
US20200023071A1 (en) 2017-02-06 2020-01-23 Innate Pharma Immunomodulatory antibody drug conjugates binding to a human mica polypeptide
EP3661552A4 (en) * 2017-05-22 2021-08-25 Dana-Farber Cancer Institute, Inc. COMPOSITIONS AND METHODS FOR INHIBITING THE ELIMINATION OF MICA / B
AU2018298673A1 (en) * 2017-07-10 2019-12-19 Innate Pharma Combination therapy using antibody to human Siglec-9 and antibody to human NKG2A for treating cancer
JP7274469B2 (ja) * 2017-10-06 2023-05-16 イナート・ファルマ・ソシエテ・アノニム Ｃｄ３９／ｃｄ７３軸によるｔ細胞活性の回復
JP7351845B2 (ja) * 2018-03-23 2023-09-27 ブリストル－マイヤーズ スクイブ カンパニー Ｍｉｃａおよび／またはｍｉｃｂに対する抗体ならびにそれらの使用
IL280487B2 (en) 2018-07-31 2025-07-01 Cullinan Mica Corp Anti-mica/b antibodies that block mica/b shedding and methods of use
WO2020035345A1 (en) 2018-08-14 2020-02-20 Innate Pharma Treatment of colorectal cancer by a combination of an anti-mica antibody and an anti-nkg2a antibody
CA3148318A1 (en) * 2019-08-23 2021-03-04 Jennifer D. Wu Materials and methods for activating antigen-specific t cell responses
IL293552A (en) * 2019-12-05 2022-08-01 Vycellix Inc Modulators of the immune escape mechanism for universal cell therapy
CN111471099B (zh) * 2020-03-31 2022-04-12 长沙学院 MICA胞外区突变体及其筛选的方法、scFv-MICA融合抗体及其制备方法和应用
CN111718416B (zh) * 2020-06-25 2022-04-01 菲鹏生物股份有限公司 抗硫氧还蛋白的抗体、其应用和诊断试剂盒
EP4178678A1 (en) 2020-07-07 2023-05-17 Cancure, LLC Mic antibodies and binding agents and methods of using the same
CA3186062A1 (en) 2020-08-10 2022-02-17 Marion BENEZECH Cell surface mica and micb detection using antibodies
CN112694532B (zh) * 2021-01-12 2023-04-18 倍而达药业（苏州）有限公司 抗Siglec-15的抗体或其抗原结合片段及应用
CN113502265B (zh) * 2021-05-25 2024-05-28 昭泰英基生物医药（香港）有限公司 将t细胞重编程为类nk细胞的诱导剂及其应用
CN115611982B (zh) * 2021-07-14 2024-05-10 浙江大学 一种抗人MICA/Bα3区的单克隆抗体及其应用
CN114369161B (zh) * 2021-12-28 2023-06-23 合肥天港免疫药物有限公司 Mica抗体及其应用
CN114369162B (zh) * 2021-12-28 2023-05-30 合肥天港免疫药物有限公司 抗体及其应用
CN118027195B (zh) * 2023-05-06 2025-07-04 合肥天港免疫药物有限公司 亲和力成熟的mica抗体及其应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
WO1996030511A1 (en) * 1995-03-29 1996-10-03 The Immunogenetics Research Foundation Incorporated Polymorphic and multicopy members of mhc gene families
WO1998019167A2 (en) 1996-10-29 1998-05-07 Fred Hutchinson Cancer Research Center, Inc. Cell stress regulated human mhc class i gene
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
PT1071700E (pt) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
ES2694002T3 (es) 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
WO2000061739A1 (fr) 1999-04-09 2000-10-19 Kyowa Hakko Kogyo Co., Ltd. Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
NZ532526A (en) 2001-10-25 2007-01-26 Genentech Inc Compositions comprising a glycoprotein having a Fc region
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
AU2003225093A1 (en) * 2002-04-22 2003-11-03 Fred Hutchinson Cancer Research Center Soluble mic polypeptides as markers for diagnosis, prognosis and treatment of cancer and autoimmune diseases or conditions
JP4459810B2 (ja) 2002-08-14 2010-04-28 マクロジェニクス，インコーポレーテッド ＦｃγＲＩＩＢ特異的抗体とその利用法
JP2006524039A (ja) 2003-01-09 2006-10-26 マクロジェニクス，インコーポレーテッド 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
AU2004290070A1 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
US7521542B2 (en) 2004-05-10 2009-04-21 Macrogenics, Inc. Humanized FcγRIIB-specific antibodies and methods of use thereof
US7632497B2 (en) 2004-11-10 2009-12-15 Macrogenics, Inc. Engineering Fc Antibody regions to confer effector function
AU2006255085A1 (en) 2005-06-03 2006-12-14 Genentech, Inc. Method of producing antibodies with modified fucosylation level
PL1919503T3 (pl) 2005-08-10 2015-04-30 Macrogenics Inc Identyfikacja i inżynieria przeciwciał ze zmiennymi regionami FC oraz sposoby ich stosowania
EP1949107A1 (en) 2005-11-03 2008-07-30 Fred Hutchinson Cancer Research Center Negative immunomodulation of immune responses by nkg2d-positive cd4-positive cells
FR2894982A1 (fr) 2005-12-16 2007-06-22 Lab Francais Du Fractionnement Procede de preparation d'anticorps selectifs des recepteurs fc activateurs
NZ598048A (en) 2006-01-17 2013-05-31 Synthon Biopharmaceuticals Bv Compositions and methods for humanization and optimization of n-glycans in plants
CA2644903A1 (en) 2006-03-10 2007-09-20 Macrogenics, Inc. Identification and engineering of antibodies with variant heavy chains and methods of using same
ES2489646T3 (es) 2006-05-26 2014-09-02 Macrogenics, Inc. Anticuerpos humanizados específicos a Fc gamma RIIB y sus métodos de uso
WO2008002933A2 (en) 2006-06-26 2008-01-03 Macrogenics, Inc. Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
EP1878747A1 (en) 2006-07-11 2008-01-16 greenovation Biotech GmbH Glyco-engineered antibodies
WO2008036981A1 (en) * 2006-09-22 2008-03-27 Dana-Farber Cancer Research, Inc. Methods for treating mica-related disorders
EP2150565A2 (en) * 2007-04-23 2010-02-10 Fred Hutchinson Cancer Research Center NEGATIVE IMMUNOMODULATION OF IMMUNE RESPONSES BY ERp5
EP1995309A1 (en) 2007-05-21 2008-11-26 Vivalis Recombinant protein production in avian EBx® cells
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
JP6012624B2 (ja) 2010-12-23 2016-10-25 ヤンセン バイオテツク，インコーポレーテツド 活性プロテアーゼ耐性抗体Ｆｃ突然変異体
MX355877B (es) * 2011-09-30 2018-05-03 Dana Farber Cancer Inst Inc Peptidos terapeuticos.
CN104244977A (zh) 2012-02-07 2014-12-24 先天制药公司 Mica结合剂
KR20180118673A (ko) 2016-03-15 2018-10-31 이나뜨 파르마 항-mica 항체

Also Published As

Publication number Publication date
AU2013218017B2 (en) 2017-12-07
RU2656183C2 (ru) 2018-05-31
CA2862101A1 (en) 2013-08-15
SG11201404177PA (en) 2014-08-28
CN104244977A (zh) 2014-12-24
IL233793A0 (en) 2014-09-30
JP6405242B2 (ja) 2018-10-17
US20150191542A1 (en) 2015-07-09
AU2013218017A2 (en) 2014-10-16
IL233793B (en) 2020-04-30
WO2013117647A1 (en) 2013-08-15
RU2014131317A (ru) 2016-03-27
JP2015508757A (ja) 2015-03-23
US20200299380A1 (en) 2020-09-24
EP2812027A1 (en) 2014-12-17
AU2013218017A1 (en) 2014-09-11
US10577416B2 (en) 2020-03-03

Similar Documents

Publication Publication Date Title
BR112014019611A2 (pt) agentes de ligação mica
BR112015006060A2 (pt) agentes de ligação kir3dl2
CY1122978T1 (el) Αντισωματα εναντι-vla-4
CY1122278T1 (el) Αντι il-36r αντισωματα
CO2018000211A2 (es) Moléculas de anticuerpo que se unen a cd45
BR112014028785A2 (pt) proteínas de ligação a antígeno de st2
EA201391175A1 (ru) Гетеродимерные иммуноглобулины
BR112012025568A2 (pt) proteínas de ligação ao tnf-<244>.
PH12017500864A1 (en) Anti-notch1 antibodies
CO2018000104A2 (es) Moléculas de anticuerpo que se unen a cd22
JOP20160131B1 (ar) الأجسام المضادة للعامل xi وطرق الاستخدام
BR112018006360A2 (pt) anticorpos agonísticos que se ligam especificamente ao cd40 humano e métodos de uso
BR112015021838A2 (pt) amatoxina, método de síntese, composição farmacêutica
EA201591746A1 (ru) Способы и композиции для ингибирования бромодомен-содержащих белков
CO6551686A2 (es) Inmunoglobinas con dominio variable dual y usos de las mismas
CO2018000410A2 (es) Moléculas de anticuerpo que se unen a cd79
BR112013021562A2 (pt) anticorpos para cd70
MX2019007921A (es) Nuevos agentes de union a ha.
BR112014015111A2 (pt) composições e processos para anticorpos que se direcionam ao fator p
EA201690503A1 (ru) Антитела
EA201590918A1 (ru) Антитела к bmp-6
UA105073C2 (uk) Антитіло проти фракталкіну, композиція і спосіб для лікування запальних порушень
BR112015024758A2 (pt) proteínas de fusão de ligação à cartilagem
BR112019005783A2 (pt) agentes de ligação monoclonal com cmet, conjugados de fármaco dos mesmos e usos dos mesmos
BR112013005423A2 (pt) composições de anticorpo anti-vegfr-3.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL